{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:30:20Z","timestamp":1789878620240,"version":"4.0.1"},"reference-count":39,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2007,8,7]],"date-time":"2007-08-07T00:00:00Z","timestamp":1186444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Haemophilia is often characterized by acute haemarthrosis and synovitis arising from spontaneous bleeding episodes, particularly in the muscles and joints of the elbows, knees and ankles. Current treatment for patients with severe haemophilia involves coagulation factor concentrate (CFC) replacement therapy given on demand at the time of bleeding or through long\u2010term prophylaxis aimed at preventing future bleeds and joint disease. Although prophylaxis has many advantages over on\u2010demand therapy (particularly if started before age 2 and prior to any signs of joint disease), its practice varies widely even among developed countries because of several barriers. Such barriers include CFC costs and availability; patient perceptions, lifestyles and bleeding patterns; difficulties and complications arising from the use of intravenous access devices (IVADs); the development of inhibitors; and the lack of randomized clinical trials. These barriers can be overcome by tailoring treatment regimens according to individual patient bleeding patterns and CFC pharmacokinetic profiles, using IVADs selectively and judiciously, helping patients maintain normal weight and physical exercise and providing the families of patients with continuous support from healthcare providers.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2007.01501.x","type":"journal-article","created":{"date-parts":[[2007,8,7]],"date-time":"2007-08-07T11:59:15Z","timestamp":1186487955000},"page":"16-22","source":"Crossref","is-referenced-by-count":71,"title":["Identifying and overcoming barriers to prophylaxis in the management of haemophilia"],"prefix":"10.1111","volume":"13","author":[{"given":"P.","family":"PETRINI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,8,7]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128072-200204070-00002"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00631.x"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1976.tb16525.x"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.9.s1.3.x"},{"key":"e_1_2_9_6_2","first-page":"691","article-title":"Modern treatment of haemophilia","volume":"73","author":"Berntorp E","year":"1995","journal-title":"Bull World Health Organ"},{"key":"e_1_2_9_7_2","volume-title":"MASAC Recommendations Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding)","author":"National Hemophilia Foundation","year":"2006"},{"key":"e_1_2_9_8_2","volume-title":"Guidelines for the Management of Hemophilia","author":"World Federation of Hemophilia","year":"2005"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00757.x"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00817.x"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH06-02-0125"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01189.x"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01074.x"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01463.x"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1997.130135000.x"},{"key":"e_1_2_9_16_2","first-page":"3","article-title":"Initial results of a randomized, prospective trial of prophylaxis to prevent joint disease in young children with factor VIII (FVIII) deficiency","volume":"106","author":"Manco\u2010Johnson MJ","year":"2005","journal-title":"ASH Annu Meet Abstr"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.440413.x"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00952.x"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00695.x"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00764.x"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1355-0691.2004.00880.x"},{"key":"e_1_2_9_22_2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1160\/TH04-08-0485","article-title":"Factor VIII efficient and specific non\u2010covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy","volume":"93","author":"Baru M","year":"2005","journal-title":"Thromb Haemost"},{"key":"e_1_2_9_23_2","unstructured":"PowellJ.Safety and pharmokinetic properties of rFVIII formulated with polyethylene glycolliposomes in patients with severe hemophilia A.Slide presentation at: Hemophilia 2006 World Federation of Haemophilia Congress. Vancouver BC 21\u201325 May 2006."},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-008276"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01280.x"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2001.00534.x"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01192.x"},{"key":"e_1_2_9_28_2","first-page":"189","article-title":"Use of implantable venous access devices in children with severe hemophilia: benefits and burden","volume":"89","author":"Van Dijk K","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(03)00043-2"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1998.tb01412.x"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(98)70386-5"},{"key":"e_1_2_9_32_2","first-page":"70","article-title":"Use and morbidity of venous access devices in patients with hemophilia","volume":"21","author":"Geraghty S","year":"1998","journal-title":"J Intraven Nurs"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1727"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.00921.x"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05605.x"},{"key":"e_1_2_9_36_2","unstructured":"SantagostinoE MancusoM Van der BomJet\u00a0al.Intensity of treatment\/prophylaxis and the risk to develop inhibitors among previously untreated patients with severe hemophilia: the CANAL study.Abstract presented at: Hemophilia 2006 World Federation of Haemophilia Congress. Vancouver BC 21\u201325 May 2006: Abstract 14."},{"key":"e_1_2_9_37_2","first-page":"CD003429","article-title":"Clotting factor concentrates given to prevent bleeding and bleeding\u2010related complications in people with hemophilia A or B","author":"Stobart K","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.9.s1.6.x"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01953.x"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1997.00091.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2007.01501.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2007.01501.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T10:23:54Z","timestamp":1695810234000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2007.01501.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,7]]},"references-count":39,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1111\/j.1365-2516.2007.01501.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2007.01501.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,7]]}}}